Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.

BACKGROUND Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS Patients were treated with docetaxel 35 mg/m(2) on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. RESULTS Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47%); two patients (6%) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11% of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. CONCLUSIONS Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.

[1]  L. Zelek,et al.  Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Perng,et al.  Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere) , 2001, British Journal of Cancer.

[3]  E. Small,et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Einhorn,et al.  Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Budman,et al.  Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. , 1997, British journal of urology.

[6]  A. Cesne,et al.  Docetaxel and interstitial pulmonary injury. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P M Ravdin,et al.  Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Valero,et al.  Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Tew,et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Mooney Breast diseases, 2nd edition , 1992 .

[11]  H. Scher,et al.  Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. , 1992, The Journal of urology.

[12]  K. Tew,et al.  Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. , 1992, Pharmacology & therapeutics.

[13]  Schein Ps Estramustine: historical background and preclinical trials. , 1983 .

[14]  K. Tew The mechanism of action of estramustine. , 1983, Seminars in oncology.

[15]  P. Schein Estramustine: historical background and preclinical trials. , 1983, Seminars in oncology.